Orphan Drugs In Development For The Treatment Of Friedreich's Ataxia: Focus On Omaveloxolone
{{output}}
Friedreich's Ataxia (FRDA) is a devastating and progressive ataxia, marked by mitochondrial dysfunction and oxidative stress. Nrf2 activators such as omaveloxolone (Omav) modulate antioxidative mechanisms, and thus may be viable therapeutic agents in FRDA. ... ...
